Left Atrial Appendage Closure in Patients With Contraindications to Oral Anticoagulation

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F16%3A%230006959" target="_blank" >RIV/00023884:_____/16:#0006959 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Left Atrial Appendage Closure in Patients With Contraindications to Oral Anticoagulation

Popis výsledku v původním jazyce

The PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in Patients With Atrial Fibrillation) and PREVAIL (Prospective Randomized Evaluation of the Watchman LAA Closure Device In Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy) trials revealed that in atrial fibrillation (AF) patients suitable for oral anticoagulation (OAC), mechanical left atrial appendage closure (LAAC) with a catheter-delivered heart implant device (Watchman; Boston Scientific, Marlborough, Massachusetts) is effective for stroke prevention 1 and 2. Importantly, these patients received at least 6 weeks of OAC. Although there is no randomized LAAC trial in OAC-contraindicated patients, there is 1 prospective nonrandomized study of Watchman in these patients (n = 150; CHA2DS2-VASc [Congestive heart failure; Hypertension; Age; Diabetes mellitus; prior Stroke, TIA, or thromboembolism; Vascular disease; Age; Sex category {female}] score = 4.4) (3). In this trial, ASAP (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology), the post-implantation annual ischemic stroke rate was 1.7%, representing 77% fewer strokes than expected for this population. Although promising, the mean follow-up in ASAP was only 1.2 years, so there have been few long-term data regarding LAAC in OAC-contraindicated patients. Herein, we report the 5-year follow-up of ASAP.

Název v anglickém jazyce

Left Atrial Appendage Closure in Patients With Contraindications to Oral Anticoagulation

Popis výsledku anglicky

The PROTECT AF (Watchman Left Atrial Appendage Closure Technology for Embolic Protection in Patients With Atrial Fibrillation) and PREVAIL (Prospective Randomized Evaluation of the Watchman LAA Closure Device In Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy) trials revealed that in atrial fibrillation (AF) patients suitable for oral anticoagulation (OAC), mechanical left atrial appendage closure (LAAC) with a catheter-delivered heart implant device (Watchman; Boston Scientific, Marlborough, Massachusetts) is effective for stroke prevention 1 and 2. Importantly, these patients received at least 6 weeks of OAC. Although there is no randomized LAAC trial in OAC-contraindicated patients, there is 1 prospective nonrandomized study of Watchman in these patients (n = 150; CHA2DS2-VASc [Congestive heart failure; Hypertension; Age; Diabetes mellitus; prior Stroke, TIA, or thromboembolism; Vascular disease; Age; Sex category {female}] score = 4.4) (3). In this trial, ASAP (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology), the post-implantation annual ischemic stroke rate was 1.7%, representing 77% fewer strokes than expected for this population. Although promising, the mean follow-up in ASAP was only 1.2 years, so there have been few long-term data regarding LAAC in OAC-contraindicated patients. Herein, we report the 5-year follow-up of ASAP.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of the American College of Cardiology

ISSN

0735-1097

e-ISSN

—

Svazek periodika

67

Číslo periodika v rámci svazku

18

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

3

Strana od-do

2190-2192

Kód UT WoS článku

000375406100016

EID výsledku v databázi Scopus

2-s2.0-84966526573